EBS
Emergent BioSolutions Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.06
+3.59%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$5.79
From 52W high−56.40%
Volume1.00M
Market cap$311.58M
P/E (TTM)—
P/S (TTM)0.5x
Div yield—
Key dataNov 6, 2026
Open
$5.79
From 52W high
−56.40%
Volume
1.00M
Market cap
$311.58M
ValuationView details →
P/E (Fwd)
16.1x
EV/EBITDA
−5.5x
P/E (TTM)
—
RSI (14)
38.9
MomentumView details →
1D Return
+3.59%
YTD Return
−52.51%
SummaryUpdated Sep 1, 2026
Emergent BioSolutions Inc. (NYSE:EBS) is a specialized life sciences company founded in 1998 and headquartered in Gaithersburg, Maryland. The company went public in 2006 and has evolved into a leading provider of medical countermeasures and emergency response solutions for public health threats. Emergent focuses on addressing chemical, biological, radiological, nuclear, and explosive threats, as well as emerging infectious diseases and opioid overdose emergencies. The company has undergone significant strategic transformation in recent years, streamlining operations and focusing on its core competencies in biodefense and overdose prevention.
Similar companies
Latest newsMore news →
Emergent BioSolutions Inc. reported third-quarter 2026 financial results, including revenue of $110.0 million, in line with its guidance.5d agoEmergent BioSolutions said Richard S. Lindahl will retire as executive vice president and chief financial officer effective December 31, 2026, and become a senior executive advisor on January 1, 2027; Frank Vargo will become interim chief financial officer on January 1, 2027.22d ago